Clinical development of asciminib (ABL001): A randomized phase 3 study of asciminib vs bosutinib in patients with chronic myeloid leukemia (CML) Meeting Abstract


Authors: Mauro, M. J.; Lang, F.; Kim, D. W.; Cortes, J. E.; Hughes, T. P.; Hochhaus, A.; Minami, H.; Boquimpani, C.; Minami, Y.; Breccia, M.; Goh, Y. T.; Ottmann, O.; Sondhi, M.; Hois, S.; Bédoucha, V.; Perraud, K.; Rea, D.; DeAngelo, D. J.
Abstract Title: Clinical development of asciminib (ABL001): A randomized phase 3 study of asciminib vs bosutinib in patients with chronic myeloid leukemia (CML)
Meeting Title: 6th Annual Meeting of the Society of Hematologic Oncology (SOHO 2018)
Keywords: inhibitor; chronic myeloid leukemia; tyrosine kinase; bosutinib; asciminib; abl001
Journal Title: Clinical Lymphoma, Myeloma and Leukemia
Volume: 18
Issue: Suppl. 1
Meeting Dates: 2018 Sep 12-15
Meeting Location: Houston, TX
ISSN: 2152-2650
Publisher: Elsevier Inc.  
Date Published: 2018-09-01
Start Page: S223
Language: English
ACCESSION: WOS:000444343400144
DOI: 10.1016/j.clml.2018.07.094
PROVIDER: wos
Notes: Meeting Abstract: CML-063 -- Source: Wos
Altmetric Score
MSK Authors
  1. Michael John Mauro
    134 Mauro